Limited and External Funding Opportunities

Contact us...

  • Email LSO@vanderbilt.edu if you are interested in an opportunity not listed below or have questions regarding the LSO submission process.

 

Have you been awarded a Limited Submission recognition?

Please let us know at LSO@vanderbilt.edu


Research Awards Banner.png

Active Internal Calls for Limited Submission Nominations 

Internal review process required to choose institutional nominees


Limited Submission Eligibility Guidelines

The following tags serve as a guide for submission instructions.

 Vanderbilt (VU + VUMC):  

  • VU and VUMC submit collaboratively to this LSO. ALL investigators should follow the guidelines posted on this site.

 VUMC :

  • VU and VUMC submit separately to this LSO. VUMC investigators should follow the guidelines posted on this site. VU investigators should apply through InfoReady and address any questions to VU-LSO@vanderbilt.edu.

FEATURED OPPORTUNITY

  • High-profile or prestigious awards of particular interest to Vanderbilt investigator

NIH Director’s Early Independence Awards (DP5 Clinical Trial Optional)

Applications due June 30, 2022

VUMC: These instructions are for VUMC investigators. VU investigators should apply through InfoReady and address any questions to VU-LSO@vanderbilt.edu.

VUMC may submit two applications to the NIH Director's Early Independence Award.

The NIH Director's Early Independence Award (DP5 Clinical Trial Optional) supports exceptional investigators who wish to pursue independent research essentially after completion of their terminal doctoral/research degree or end of post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce.

Though most newly graduated doctoral-level researchers would benefit from post-doctoral training, a small number of outstanding junior investigators are capable of launching directly into an independent research career. The Early Independence Award is intended for these select junior investigators who have already established a record of scientific innovation and research productivity and have demonstrated unusual scientific vision and maturity; typical post-doctoral training would unnecessarily delay their entry into independent research. The NIH Director’s Early Independence Award also provides an opportunity for institutions to invigorate their research programs by bringing in fresh scientific perspectives of the awardees they host.

By the end of the award period, the Early Independence Award investigator is expected to be competitive for continued funding of his/her research program through other NIH funding activities and for a permanent research-oriented position.

Eligibility

  • Individuals from diverse backgrounds, including those from underrepresented groups and from the full spectrum of eligible institutions in all geographic locations, are strongly encouraged to apply.
  • Applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. The NIH Director's Early Independence Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund.
  • Time window for eligibility: The receipt date of the terminal doctoral degree or end of post-graduate clinical training of the PD/PI must be between June 1, 2021 and September 30, 2023. The degree receipt date is that which appears on the official transcript for the degree. The end of post-graduate clinical training includes residency and fellowship periods.
  • At the time of application, the PD/PI must not have served as a post-doctoral fellow for more than twelve months following a previous, non-terminal doctoral degree before June 1, 2021. . To be consistent with the updated NIH definition of Early Stage Investigators, eligible clinical training includes clinical residency and clinical fellowship.
  • Research independence at time of application: Individuals are eligible only if they, at the time of application submission, do not have research independence. Eligible individuals must have all the following characteristics:
    • The PD/PI's current research agenda is set through concurrence with mentors;
    • The PD/PI's research is funded primarily through support to other investigators (mentored fellowships such as NIH F31 or F32 Fellowships or NSF Graduate Research Fellowships do not preclude eligibility);
    • The PD/PI does not have any space assigned directly by the institution for the conduct of his/her research;
    • The PD/PI, according to institutional policy, cannot apply for an NIH R01 grant without special waiver or exemption from the institution.
  • There is no U.S. citizenship requirement for PDs/PIs.

Level of effort: Individuals must commit at least 9.6 person-months each year (i.e., 80% effort of a 12-month appointment) to the Early Independence Award project in years 1-2 of the project period. In years 3-5, awardees may reduce effort towards the Early Independence Award project but must commit at least 9.6 person-months each year (i.e., 80% effort of a 12-month appointment) to independent research in general.

Budget Info: Awards will be for up to $250,000 direct costs per year for a period of 5 years, plus applicable Facilities and Administrative (F&A) costs.

See the RFA for more information.

Internal Application Process:

Anyone interested in being one of VUMC’s nominees must submit the following (in a single PDF) to LSO@vanderbilt.edu  by June 30, 2022.

  1. Brief (2-page maximum) research plan including summary budget;
    1. Include three sections with the following headings to mirror the specific aims format: "Research Objectives," "Institutional Support," and "Early Independence Rationale."
  2. Statement of support from department chair/center director;
    1. The letter must address requirements for Institutional Resources & Career Development Commitment, specifically: allocated laboratory space, institutional financial commitment to investigator, and plans for mentoring and assuring scientific independence.
  3. NIH Biosketch

Submissions should reference “NIH Director’s Award” in the subject line of the email. Any questions about this opportunity or the LSO process may be directed to LSO@vanderbilt.edu.


NIH Bridges to the Doctorate Research Training Program (T32)

Applications due June 30, 2022

Vanderbilt (VU + VUMC): This is a joint competition for VU and VUMC investigators. All investigators should follow these instructions.

Vanderbilt (VU+VUMC) may submit may submit 1 application as the lead institution for the Bridges to the Doctorate Research Training Program (T32).

The goal of the Bridges to the Doctorate Research Training program is to develop a diverse pool of scientists earning a Ph.D., who have the skills to successfully transition into careers in the biomedical research workforce. This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-based approaches to biomedical training and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation.

Each Bridges to the Doctorate Research Training Program must consist of a strong partnership/consortium composed of at least two institutions: an institution that offers the master's degree as the terminal graduate degree in the biomedical sciences, and a research-intensive college or university granting Ph.Ds. in the biomedical sciences. Each program should provide high-quality training that equips individuals with the technical (e.g., appropriate methods, technologies, and quantitative/computational approaches), operational (e.g., independent knowledge acquisition, rigorous experimental design, and interpretation of data, conducting research in the safest manner possible) and professional (e.g., management, leadership, communication, and teamwork) skills required for careers in the biomedical research workforce. Funded programs are expected to promote inclusive research environments (i.e., institutional and departmental environments where trainees from all backgrounds are and feel integrated into and supported by the biomedical research community).

This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

Application budgets are not limited but need to reflect the actual needs of the proposed project.

See the solicitation for more information.

Internal Application Process:

Anyone interested in being considered as Vanderbilt’s potential nominee must submit the following (in PDF format) to LSO@vanderbilt.edu by 5 p.m. on June 30, 2022.  

  • Brief (2-page maximum) project description, with a summary budget
  • Proposed list of Vanderbilt key personnel and collaborators
  • NIH Biosketch or 5-page CV for each PI/PD
  • Statement of support from department chair/center director

Any questions about this opportunity or the LSO process may be directed to LSO@vanderbilt.edu


NIH Bridges to the Baccalaureate Research Training Program (T34)

Applications due June 30, 2022

Vanderbilt (VU + VUMC): This is a joint competition for VU and VUMC investigators. All investigators should follow these instructions.

Vanderbilt University may submit only one application as the lead institution for the Bridges to the Baccalaureate Research Training Program (T34).

The goal of the Bridges to the Baccalaureate Research Training Program is to provide structured activities to prepare a diverse cohort of research-oriented students to transfer from associate degree-granting institutions to baccalaureate degree-granting institutions and complete a baccalaureate degree in disciplines related to the biomedical sciences. This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-informed approaches to biomedical training and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring, and career development elements.

This program requires strong partnerships between at least two post-secondary educational institutions offering science, technology, engineering, or mathematics (STEM) degrees.  At least one partner must be an institution that offers the associate degree as the highest STEM degree and the other partner(s) must offer baccalaureate degrees in biomedically relevant STEM fields. Upon completion of the Bridges to the Baccalaureate Research Training program, trainees are expected to be well positioned to pursue research-oriented biomedical higher degree programs or enter careers in the biomedical research workforce.

This FOA does not allow appointed trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor. NIH strongly supports training towards a career in clinically relevant research and so gaining experience in clinical trials under the guidance of a mentor or co-mentor is encouraged.

Application budgets are not limited but need to reflect the actual needs of the proposed project.

See the FOA for more information.

Internal Application Process:

Anyone interested in being considered to submit Vanderbilt’s proposal must submit the following materials via Infoready by 5 p.m. on June 30, 2022:

  • 2-page project description w/ summary budget
  • CV/Biosketch
  • Statement of support from department chair/center director

Any questions about this opportunity or the LSO process may be directed to LSO@vanderbilt.edu


2023 Searle Scholars Program

Applications due July 11, 2022

VUMC: These instructions are for VUMC investigators. VU investigators should apply through InfoReady and address any questions to VU-LSO@vanderbilt.edu.

Overview:

VUMC may nominate two candidates for the 2023 Searle Scholars Program, which supports the independent research of outstanding individuals who have recently begun their first appointments as tenure-track assistant professors.  The Searle Scholars Program Scientific Advisory Board is primarily interested in the potential of applicants to make innovative and high-impact contributions to biomedical research over an extended period of time. Each year, 15 new individuals are named Searle Scholars and awarded $300,000 over three years.

Eligibility:

  • Applicants are expected to be pursuing independent research careers in biochemistry, cell biology, genetics, immunology, neuroscience, pharmacology, and related areas in chemistry, medicine, and the biological sciences.
  • Applicants should have begun their appointment as an independent investigator at the assistant professor level on or after July 1, 2021. The appointment must be their first tenure-track position, or its nearest equivalent.
  • The Program does not support purely clinical research but has supported research programs that include both clinical and basic components.
  • Applicants who were nominated for awards in the previous competition year but were not awarded may still meet the eligibility criteria for the current competition. *Contact LSO@vanderbilt.edu if this applies.

Potential applicants who are unsure if their research is appropriate for the Program are encouraged to examine the research interests of present and former Searle Scholars.

See the Eligibility, FAQs, and Award Information sections for more information.   

Internal Application Process:

Eligible faculty interested in being one of VUMC’s nominees must submit the following (in a single PDF) to LSO@vanderbilt.edu  by 5 p.m. on July 11, 2022: 

  1. Brief (2-page maximum) research plan including summary budget (overhead not allowed);
  2. Letter of support from department chair/center director;
    1. Letter must also acknowledge that this grant does not allow indirect costs. This statement can be used/modified within the letter: “The Department recognizes that this grant does not allow indirect costs and will commit to covering any associated indirect costs per applicable institutional policy.”
  3. NIH Biosketch

Submissions should reference the program name in the subject line of the email.

Any questions about this opportunity or the LSO process may be directed to LSO@vanderbilt.edu.


2022 Procter & Gamble Higher Education Grant Program

Vanderbilt (VU + VUMC): This is a joint competition for VU and VUMC investigators. All investigators should follow these instructions.

Applications due July 14, 2022

Vanderbilt University may submit 2 applications from each School for the Procter & Gamble Higher Education Grant Program. The program provides support for efforts that will better prepare students for success in business (see examples below). Grant support is for 1 year and awards range between $10,000-$20,000 (no overhead costs allowed). Grants will be provided for specific projects or programs, not for operating support, stipends, or fellowships.

Examples of eligible projects include, but are not limited to:

  • Improving curriculum to be at the cutting edge in relevance and effectiveness;
  • Fostering and enabling leadership opportunities and learning;
  • Creating a learning environment that encourages and enhances innovation and creativity;
  • Strengthening diversity in thought, participation and ongoing interaction.

See the program page and flyer for more information.

Application Process

Interested faculty should visit https://vanderbilt.infoready4.com/#competitionDetail/1874388 to submit the materials below and to find additional information about the opportunity.  The deadline for the internal competition is July 14, 2022.

  • Brief (2-page max) project description including summary budget
  • NIH Biosketch or 5-page CV
  • Brief letter of support from department chair/center director
    • The letter must also acknowledge that this grant does not allow indirect costs and will commit to covering any associated indirect costs per applicable school/departmental policy.

Any questions about this opportunity or the LSO process may be directed to LSO@vanderbilt.edu.


 

 

Research Awards Banner.png

Active Calls for NON-Limited External Opportunities 

Internal review process NOT required- Submit directly to Sponsor

The VUMC Corporate & Foundation Relations team provides hands-on proposal development assistance for non-federal awards. Contact cfr@vumc.org for more information.


 

DOD CDMRP Vision Research Program (VRP) - Multiple Award Types

Pre-applications due July 15; Full applications due November 9

Clinical Trial Award (CTA): Supports the rapid implementation of early-phase clinical trials (i.e., phase 0 through phase 2a) of new interventions to service-related eye injury and visual dysfunction.

Focused Translational Team Science Award (FTTSA): Supports a team initiative that leverages the strengths of investigators specializing in different fields to address an overarching scientific challenge or question and fundamentally advance the understanding and treatment of military-relevant vision trauma/dysfunction.

Investigator-Initiated Research Award (IIRA): Supports studies that will yield highly impactful discoveries or major advancements in research and/or patient care.

Translational Research Award (TRA): Supports translational research that moves promising laboratory research into clinical applications.

 


Susan G. Komen Career Catalyst Research Grant

Letters of Intent due July 15

For over 10 years, Susan G. Komen® Career Catalyst Research (CCR) Grants have fostered promising breast cancer researchers who are in the early stages of their faculty careers by providing support for up to three years of “protected time” for research career development under the guidance of a Mentor Committee. This award provides up to $150,000 per year (combined direct and indirect costs) for up to three years ($450,000).

Early career breast cancer researchers who have held faculty positions for no more than 6 years by the application due date (October 5, 2022) are invited to apply.

FY23 CCR Topic:

Advancing Precision Medicine and Improving Breast Cancer Outcomes for All

The goal of the FY23 CCR Grant mechanism is to support outstanding research focused on two important aspects of precision medicine: the development of next generation-targeted therapies and the development of interventions to eliminate breast cancer health disparities. Proposals that are basic, translational, clinical or population sciences and meet at least one of the following focus areas will be considered.

  • Beyond PARP inhibitors: Next generation breast cancer therapies targeting the genome and epigenome
  • Beyond T-Cells: Next generation breast cancer immunotherapy
  • Closing the Gap: New approaches to address multi-level contributors to breast cancer disparities

For more information on the focus areas, eligibility, and LOI guidelines view the RFA here.


Alzheimer's Drug Discovery Foundation- Harrington Scholar Program

Letters of Intent due July 18

Interested applicants are strongly encouraged to contact Adele White, Foundation Relations (adele.white@vumc.org) before starting an application.

The ADDF-Harrington Scholar Program is dedicated to advancing academic discoveries into medicines for Alzheimer’s disease and related dementias. This unique award provides funding and committed project support by a team of pharmaceutical industry experts through a collaboration with the Alzheimer’s Drug Discovery Foundation (ADDF) and Harrington Discovery Institute. This is a special funding opportunity separate from ADDF’s Core Funding Programs.

NOTE Funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones (see Our Research Strategy for more information).

Average Award: Up to $600,000 over 2 years with dedicated support from a team of industry veterans with capabilities that include medicinal chemistry, pharmacology & toxicology, and business development. The expertise of each team is tailored to the specific needs of the project during the two-year award period.

Deadlines: 
Letter of Intent: July 18th, 2022, 5:00 PM EDT
Full Proposal: October 24th, 2022, 5:00 PM EDT

  • Eligibility Criteria:
  • Academic investigators at accredited medical centers, research institutions, and universities in the United States, Canada and United Kingdom only are eligible to apply.
  • Lead investigator must have an MD, a PhD, or equivalent.
  • Proposals should show potential to advance discovery into meaningful therapeutics to treat, prevent, or slow Alzheimer’s disease or related dementias.
  • Team should possess intellectual property (IP) or have potential for novel IP that has not yet been licensed to a for-profit entity.
  • Researchers working on drug development programs that are relevant to but not presently focused on the Alzheimer’s field are encouraged to apply.

Funding Priorities: The 2022 ADDF-Harrington Scholar RFP places high priority on targets related to emerging therapeutic areas for dementia, particularly:

  • Epigenetics (including nucleosome dynamics, chromatin remodeling, DNA methylation, histone modifications [methylation, acetylation, phosphorylation, ubiquitylation, sumoylation], bromodomain protein modulators, isocitrate dehydrogenase modulators)
  • Neurovascular health (including blood brain barrier function and integrity, cerebral hypoperfusion, nutrient supply to the brain, endothelial interaction with pericytes and astrocytes)
  • Other novel targets are encouraged. These include, but are not limited to:
    • Proteostasis
    • Neuroprotection
    • Synaptic activity and neurotransmitters
    • Inflammation
    • Mitochondria & metabolic function
    • ApoE
    • Other aging targets (e.g. senescent cells)

Any therapeutic target that has a clear marker of target engagement or one in development will be considered of high priority. Please note: This RFP does not support anti-amyloid approaches (e.g. Abeta vaccines, beta- or gamma-secretase inhibitors) or cholinesterase inhibitors. Any approaches targeting tau should be differentiated from those in clinical development.

Stage of Discovery: The ADDF-Harrington Scholar award supports programs at the hit-to-lead optimization stage through investigational new drug (IND)-enabling studies. A lead structural series must already be identified at the time of application. Applicants are encouraged to provide hit validation data including dose-response curves, analog structure-activity relationship (SAR) results, and comparison data against known molecules with a similar mechanism or mode of action. Additionally, where animal model data are reported, please include PK data supporting choice of dosing and study design. This RFP does not support target discovery, assay development or high throughput screening campaigns.

Read more about the program here: https://www.alzdiscovery.org/research-and-grants/funding-opportunities/…


NIH Director’s New Innovator Award Program (DP2)

Applications due August 19
https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-22-019.html 
The NIH Director’s New Innovator Award Program supports early stage investigators with the potential to strongly impact areas relevant to NIH’s mission. Part of the High-Risk, High-Reward Research program, the award supports exceptionally creative early career investigators who propose innovative, high-impact projects in the biomedical, behavioral or social sciences. Key points include: 
•    Single PI only
•    Must have Early Stage Investigator status (completed doctoral degree or postgraduate clinical training within last 10 years and never received a substantial NIH independent research award)
•    No preliminary data required
•    Minimum of 25% research effort
•    $1.5 million in direct costs split into two multi-year segments
For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds are strongly encouraged to apply. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. 


NIH Director’s Transformative Research Awards (R01 Clinical Trial Optional)

Applications due September 1

The NIH Director’s Transformative Research Award Program supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the nation’s research workforce. Individuals from diverse backgrounds, including those from underrepresented groups (see, Notice of NIH's Interest in Diversity, NOT-OD-20-031) are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications are welcome from the full spectrum of eligible institutions in all geographic locations and in all topic areas relevant to the broad mission of NIH, including, but not limited to, behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact in a broad area of relevance to the NIH. The NIH Director’s Transformative Research Award is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund.

Towards the objective of funding the best possible science, the Office of Strategic Coordination and the Center for Scientific Review are piloting a process for initial peer review of applications received in response to this FOA in which the identity of the investigators and institutions are withheld until the last phase of review. Instructions for anonymizing components of the application are given in Section IV and must be carefully followed. A description of the review process is given in Section V.

Application budgets are not limited but must be commensurate with the scope of the proposed research. The maximum project period is five years.


National Institute of Mental Health (NIMH) Instrumentation Program (S10 Clinical Trial Not Allowed)

Letter of Intent due September 7

Please note that this is separate from the annual ORIP S10 Program that requires institutional coordination. Email amy.f.martinez@vumc.org with any questions.

The NIMH Instrumentation Program encourages applications from NIH funded investigators to purchase or upgrade a single commercially available instrument or to purchase a group of components to create an instrument that is not commercially available. The goal of the NIMH Instrumentation Program is to make such instruments available to either individual laboratories or core facilities that conduct mental health-related research. Examples of instruments that might be submitted under this Funding Opportunity Announcement (FOA) include light microscopes, electron microscopes, spectrophotometers, and biomedical imagers. 

Background

Modern mental health-related research can require expensive instruments that are often hard to obtain through traditional funding mechanisms. The goal of the NIMH Instrumentation Program is to make such instruments available to either individual laboratories or core facilities that conduct mental health-related research. These instruments can be commercial instruments or collections of components that others have already described how to assemble into a working instrument. Upgrades of existing instruments can also be requested.

Investigators can propose instruments that will be used by their laboratory or by a collection of investigators. Investigators who are proposing to provide the instrument only to members of their laboratory must state why the instrument cannot be shared. In either case, investigators are strongly encouraged to house the requested instrument in a core facility or other shared facility to ensure that the new instrument remains functional and available to the research community over its useful lifetime.

Research Objectives

Types of instruments that might be appropriate for the NIMH Instrumentation Program include light microscopes, electron microscopes, spectrophotometers, and biomedical imagers. This list is representative and not exhaustive. Foreign-made instruments are allowed. A single application cannot request multiple unrelated instruments. In such cases, multiple applications can be submitted.

The goal of this FOA is to provide instruments to collect data rather than components for further instrument/technology development. Instrument development applications should be submitted to other FOAs on which NIMH participates or to appropriate BRAIN Initiative FOAs.

Non-Responsive Applications

The NIMH Instrumentation Program will not support requests for:

  • Purely instructional equipment
  • Instruments used for billable clinical care
  • Institutional administrative management systems
  • Stand-alone computer systems or software (Computers and software that are a component of an instrument, for example for an MRI console are responsive. An application containing only a stand alone computer systems or software is not responsive.)
  • General purpose equipment, an assortment of instruments to furnish a research facility, or equipment for routine sustaining infrastructure (such as autoclaves, hoods, cages for animal facilities, standard machine shop equipment)
  • Equipment or components that are part of an effort to develop new instruments rather than to collect data
  • Multiple unrelated instruments or components. Note: in such cases, multiple applications can be submitted.

Award Budget

Applications will be accepted with an award budget between $200,000 and $600,000. There is no maximum limit on the cost of the instrument, but the maximum award is $600,000. S10 awards are only for the cost of the instrument, so indirect costs cannot be requested.


Gilead's Research Scholars Program in HIV

Applications due September 9

Interested applicants are strongly encouraged to contact Jenny Alexander, Foundation Relations (jenny.alexander@vumc.org) before starting an application.

The Research Scholars Program supports innovative basic and clinical research from emerging investigators around the world to incorporate new perspectives in our pursuit of scientific understanding and progress. We believe that new voices and research topics are needed to advance scientific knowledge in areas of unmet medical need and create a healthier world.

The program is designed to support basic and clinical research in the field of HIV, in North America and globally.  Areas of research may include, but are not limited to:

  • Basic, clinical, behavioral, epidemiological, implementation science and community-based participatory research
  • Management of complications, comorbidities and/or co-infections e.g. HIV and aging 
  • HIV Prevention
  • Health economics outcomes research

The program provides financial support to the institutions of 4 junior faculty researchers for a 2-year period. Each award is funded up to $180,000 USD (inclusive of any indirect costs), to be paid in annual installments of up to $90,000 USD per year for 2 years. Funding for the second year is contingent upon submission of a progress report by each junior faculty researcher and approval by the Co-Chairs of the Scientific Review Committee which oversees the program.

Eligibility

This award is intended for junior faculty who meet the criteria for Early Stage Investigator, as defined by the National Institutes of Health (NIH) (https://grants.nih.gov/policy/early-investigators/index.htm).  Note, those who have received substantial NIH research awards, such as being a PI on an R01, P01, or U01, are not Early Stage Investigators, according to NIH criteria.  A list of NIH grants that a PI can hold and still be considered an Early Stage Investigator can be found at: https://grants.nih.gov/policy/early-investigators/list-smaller-grants.h…;

In addition, applicants must meet the following requirements:

  • Hold an MD, DO, PhD, or equivalent degree at time of award
  • Received your initial faculty appointment within the last 5 years at the time of application
  • Have a strong career interest in HIV
  • Have a research mentor with extensive experience in their field (co-mentorship is accepted)
  • Be able to devote approximately 50% of professional time to research (versus administrative, patient care, or teaching responsibilities)
  • Be able to complete the proposed research within the 2-year award period, providing evidence (manuscript, presentation, or abstracts) for future research projects.
  • An applicant must be a citizen or permanent resident of the United States or subject to the qualifications noted below hold a temporary non-immigrant visa/work permit 

The Research Scholars Program is actively working towards reducing potential barriers to entry and success for applicants from population groups who are typically underrepresented in research.  Award selections are made without discrimination based on race, ethnicity, religion, national origin, gender, age, sexual orientation, physical or mental disability, genetic information or characteristic, gender identity and expression. The program is committed to supporting researchers and research projects addressing unmet patient needs and health inequities in order to build a more inclusive research landscape. 


NIH Director’s Pioneer Award Program (DP1)

Applications due September 9

The NIH Director’s Pioneer Award Program supports individual scientists of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. In the Pioneer Award program, emphases are on the qualities of the investigator, the innovativeness, and potential impact of the proposed research. Key points include: 
•    Single PI only
•    No preliminary data or detailed experimental plans required
•    The proposed research must reflect substantially different ideas from those being pursued in the investigator's current research program or elsewhere. It cannot be an obvious extension or scale-up of a current research enterprise.
•    Minimum of 51% research effort for first three years of the project period. May reduce effort to minimum of 33% and 25% in the fourth and fifth years, respectively.
•    Awards will be for $700,000 in direct costs per year for the project period limited to five years.

For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds are strongly encouraged to apply. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. 


Maximizing Investigators' Research Award for Early Stage Investigators (R35)

Applications due October 3

https://grants.nih.gov/grants/guide/pa-files/PAR-20-117.html

The Maximizing Investigators’ Research Award for Early Stage Investigators (ESI MIRA) supports an ambitious program of NIGMS-related research in an early stage investigator's laboratory. The overall goal of MIRA is to increase the efficiency and efficacy of NIGMS funding. Specific MIRA benefits include:

  • No requirement or expectation for preliminary data, which will

    • Enable investigators to apply earlier in their independent research career, allowing them to secure grant funding that will launch and sustain a successful research career, and

    • Enhance investigators’ ability to move into research areas that are distinct from those of their postdoctoral mentors, which could increases chances for new scientific discoveries;

  • Increased stability of funding for NIGMS-supported ESIs, improved success rates, and more graduated, rather than all-or-none, funding decisions for MIRA renewals;

  • Larger award amount than the current average NIGMS R01 award to ESIs, while the project period will be similar;

  • More flexibility to pursue new ideas and opportunities as they arise during the course of research because the award is not tied to specific aims;

  • A reduction in administrative burden associated with managing multiple grants; and

  • A reduction in required application writing.

The ESI MIRA program encourages eligible applicants to submit an ESI MIRA application early in their independent research careers and to move into research areas that are distinct from those of their postdoctoral mentors. Applicants who have not yet received independent research funding are encouraged to apply, as are those who have not had sufficient time and/or resources to generate independent senior author publications.